Capitolis Liquid Global Markets LLC Purchases 1,351,000 Shares of Pfizer Inc. $PFE

Capitolis Liquid Global Markets LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 683.7% in the third quarter, Holdings Channel reports. The fund owned 1,548,600 shares of the biopharmaceutical company’s stock after purchasing an additional 1,351,000 shares during the quarter. Capitolis Liquid Global Markets LLC’s holdings in Pfizer were worth $39,458,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank increased its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. ABN Amro Investment Solutions purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $1,784,000. Finally, CFO4Life Group LLC raised its holdings in shares of Pfizer by 2.8% in the second quarter. CFO4Life Group LLC now owns 26,041 shares of the biopharmaceutical company’s stock worth $631,000 after buying an additional 707 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PFE. Royal Bank Of Canada initiated coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. UBS Group began coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Finally, Bank of America reduced their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.05.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Trading Down 1.0%

NYSE PFE opened at $26.60 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market capitalization of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47. The company has a fifty day moving average of $26.50 and a 200 day moving average of $25.52.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $0.63 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.